Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

544 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction.
Wachtell K, Palmieri V, Olsen MH, Bella JN, Aalto T, Dahlöf B, Gerdts E, Wright JT Jr, Papademetriou V, Mogensen CE, Borch-Johnsen K, Ibsen H, Devereux RB. Wachtell K, et al. Among authors: palmieri v. Am Heart J. 2002 Feb;143(2):319-26. doi: 10.1067/mhj.2002.119895. Am Heart J. 2002. PMID: 11835038 Clinical Trial.
Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study).
Gerdts E, Papademetriou V, Palmieri V, Boman K, Björnstad H, Wachtell K, Giles TD, Dahlöf B, Devereux RB; Losartan Intervention For End (LIFE) point reduction in hypertension study. Gerdts E, et al. Among authors: palmieri v. Am J Cardiol. 2002 Feb 15;89(4):399-402. doi: 10.1016/s0002-9149(01)02260-3. Am J Cardiol. 2002. PMID: 11835919
Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy.
Olsen MH, Wachtell K, Bella JN, Palmieri V, Gerdts E, Smith G, Nieminen MS, Dahlöf B, Ibsen H, Devereux RB. Olsen MH, et al. Among authors: palmieri v. Am J Hypertens. 2005 Nov;18(11):1430-6. doi: 10.1016/j.amjhyper.2005.05.030. Am J Hypertens. 2005. PMID: 16280277 Clinical Trial.
In-treatment midwall and endocardial fractional shortening predict cardiovascular outcome in hypertensive patients with preserved baseline systolic ventricular function: the Losartan Intervention For Endpoint reduction study.
Wachtell K, Gerdts E, Palmieri V, Olsen MH, Nieminen MS, Papademetriou V, Boman K, Dahlöf B, Aurigemma GP, Rokkedal JE, Devereux RB. Wachtell K, et al. Among authors: palmieri v. J Hypertens. 2010 Jul;28(7):1541-6. doi: 10.1097/HJH.0b013e328339f943. J Hypertens. 2010. PMID: 20410835 Clinical Trial.
In-treatment reduced left atrial diameter during antihypertensive treatment is associated with reduced new-onset atrial fibrillation in hypertensive patients with left ventricular hypertrophy: The LIFE Study.
Wachtell K, Gerdts E, Aurigemma GP, Boman K, Dahlöf B, Nieminen MS, Olsen MH, Okin PM, Palmieri V, Rokkedal JE, Devereux RB. Wachtell K, et al. Among authors: palmieri v. Blood Press. 2010 Jun;19(3):169-75. doi: 10.3109/08037051.2010.481811. Blood Press. 2010. PMID: 20438307
Prognostic significance of left ventricular diastolic dysfunction in patients with left ventricular hypertrophy and systemic hypertension (the LIFE Study).
Wachtell K, Palmieri V, Gerdts E, Bella JN, Aurigemma GP, Papademetriou V, Dahlöf B, Aalto T, Ibsen H, Rokkedal JE, Devereux RB. Wachtell K, et al. Among authors: palmieri v. Am J Cardiol. 2010 Oct 1;106(7):999-1005. doi: 10.1016/j.amjcard.2010.05.032. Am J Cardiol. 2010. PMID: 20854964 Clinical Trial.
544 results